Tango Therapeutics plans to begin a frontline pancreatic cancer phase three study in the first half of next year, enrolling 240 patients in each arm with response rate and progression-free survival as dual primary endpoints.
TNGX · Tango Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 55%
- Latest filing
- 10-Q · Nov 9
- Price history
- Sep 2020 to Nov 2026
Latest documents
Tango Therapeutics reported 82% ORR and 88% PFS for vopimetostat plus daraxonrasib in pancreatic cancer, plans Phase 3 in first half of 2027, and held $977.5 million in cash, cash equivalents and marketable securities at September 30, 2026.
Tango Therapeutics reported an 82% ORR for vopimetostat plus daraxonrasib in 22 efficacy-evaluable patients with MTAP-deleted/RAS-mutant PDAC and plans a global, randomized registrational trial in first-line PDAC in the first half of 2027.
Tango's updated data for vopametistat with Diracxon RASIB in pancreatic cancer show an objective response rate of 82% among 22 patients with metastatic pancreatic cancer and a nine-month progression-free survival rate of 88%. The company plans to start a Phase III study in first-line MTAP-deleted pancreatic cancer, anticipated to enroll 484 patients, in the first half of 2027. It also plans to start a study in MTAP wild-type pancreatic cancer in the first half of 2027.
Tango Therapeutics reported an 82% objective response rate for vopimetostat plus daraxonrasib in 22 efficacy-evaluable patients with second line or third line MTAP-deleted/RAS-mutant pancreatic cancer. It plans to start a randomized registrational trial in front-line MTAP-deleted pancreatic cancer in the first half of 2027. It also intends to reduce its workforce by approximately 14% as part of a strategic reprioritization.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash position | $977.5M | As of September 30, 2026 | — |
| Discovery direct program expenses - R&D | 2.84M | the three months ended September 30, 2026 filing | — |
|
|
|||
| Facilities and other related expenses - R&D | 5.06M | the three months ended September 30, 2026 filing | — |
|
|
|||
| Personnel-related expenses - R&D | 17.08M | the three months ended September 30, 2026 filing | — |
|
|
|||
| TNG260 direct program expenses - R&D | 1.45M | the three months ended September 30, 2026 filing | — |
|
|
|||
| TNG456 direct program expenses - R&D | 2.42M | the three months ended September 30, 2026 filing | — |
|
|
|||
| TNG908 direct program expenses - R&D | 402K | the three months ended September 30, 2026 filing | — |
|
|
|||
| vopimetostat direct program expenses - R&D | 19.67M | the three months ended September 30, 2026 filing | — |
|
|
|||
| TNG961 direct program expenses | $59K | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TNGX
this stock
Tango Therapeutics, Inc.
|
$3.85B | +156.3% | +48.3% | — | 28.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 25
Tango Therapeutics plans to begin a frontline pancreatic cancer phase three study in the first half of next year, enrolling 240 patients in each arm with response rate and progression-free survival as dual primary endpoints.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TNGX | -8.6% | -18.7% | -1.7% | 0.0% | +156.3% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -3.2% | -12.4% | +3.9% | +5.2% | +151.3% |